389 related articles for article (PubMed ID: 11514944)
41. Changes in isotretinoin prescribing before and after implementation of the System to Manage Accutane Related Teratogenicity (SMART) risk management program.
Mendelsohn AB; Governale L; Trontell A; Seligman P
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):615-8. PubMed ID: 15892175
[TBL] [Abstract][Full Text] [Related]
42. Analysis of laboratory data in acne patients treated with isotretinoin: is there really a need to perform routine laboratory tests?
Alcalay J; Landau M; Zucker A
J Dermatolog Treat; 2001 Mar; 12(1):9-12. PubMed ID: 12171680
[TBL] [Abstract][Full Text] [Related]
43. Pregnancy outcomes after first-trimester vaginitis drug therapy.
Rosa FW; Baum C; Shaw M
Obstet Gynecol; 1987 May; 69(5):751-5. PubMed ID: 3574801
[TBL] [Abstract][Full Text] [Related]
44. Terminations of pregnancy associated with isotretinoin use in New Zealand.
Moodie P; Jaine R; Arnold J; Metcalfe S; Bignall M; Arroll B
N Z Med J; 2011 Jul; 124(1339):59-66. PubMed ID: 21952331
[TBL] [Abstract][Full Text] [Related]
45. Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin.
Raguideau F; Mezzarobba M; Zureik M; Weill A; Ricordeau P; Alla F
Pharmacoepidemiol Drug Saf; 2015 May; 24(5):526-33. PubMed ID: 25753265
[TBL] [Abstract][Full Text] [Related]
46. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study.
Chun-Fai-Chan B; Koren G; Fayez I; Kalra S; Voyer-Lavigne S; Boshier A; Shakir S; Einarson A
Am J Obstet Gynecol; 2005 Mar; 192(3):932-6. PubMed ID: 15746694
[TBL] [Abstract][Full Text] [Related]
47. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
Doshi A
Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569
[No Abstract] [Full Text] [Related]
48. Ethical and legal aspects of teratogenic medications: the case of isotretinoin.
Moskop JC; Smith ML; De Ville K
J Clin Ethics; 1997; 8(3):264-78. PubMed ID: 9436085
[No Abstract] [Full Text] [Related]
49. Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy.
Henry D; Dormuth C; Winquist B; Carney G; Bugden S; Teare G; Lévesque LE; Bérard A; Paterson JM; Platt RW;
CMAJ; 2016 Jul; 188(10):723-730. PubMed ID: 27114489
[TBL] [Abstract][Full Text] [Related]
50. Adolescents, acne, and the side-effects of Accutane.
Novotny J
Pediatr Nurs; 1989; 15(3):247-8. PubMed ID: 2525246
[TBL] [Abstract][Full Text] [Related]
51. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study).
Fernández Liguori N; Klajn D; Acion L; Cáceres F; Calle A; Carrá A; Cristiano E; Deri N; Garcea O; Jaureguiberry A; Onaha P; Patrucco L; Riccio P; Rotta Escalante R; Saladino Ml; Sinay V; Tarulla A; Villa A
Mult Scler; 2009 May; 15(5):555-62. PubMed ID: 19299437
[TBL] [Abstract][Full Text] [Related]
52. First trimester disulfiram exposure: report of two cases.
Helmbrecht GD; Hoskins IA
Am J Perinatol; 1993 Jan; 10(1):5-7. PubMed ID: 8442800
[TBL] [Abstract][Full Text] [Related]
53. Gold therapy in women planning pregnancy: outcomes in one center.
Almarzouqi M; Scarsbrook D; Klinkhoff A
J Rheumatol; 2007 Sep; 34(9):1827-31. PubMed ID: 17696276
[TBL] [Abstract][Full Text] [Related]
54. [Isotretinoin: compliance with recommendations in childbearing women].
Bensouda-Grimaldi L; Jonville-Béra AP; Mouret E; Elefant E; Dhellot H; Delmas C; Gouin T; Coste P; Autret-Leca E;
Ann Dermatol Venereol; 2005 May; 132(5):415-23. PubMed ID: 15988352
[TBL] [Abstract][Full Text] [Related]
55. Risk of drug-induced congenital defects.
De Santis M; Straface G; Carducci B; Cavaliere AF; De Santis L; Lucchese A; Merola AM; Caruso A
Eur J Obstet Gynecol Reprod Biol; 2004 Nov; 117(1):10-9. PubMed ID: 15474237
[TBL] [Abstract][Full Text] [Related]
56. Fertility and outcomes of pregnancy after chemotherapy in a sample of childbearing aged women.
Durrieu G; Rigal M; Bugat R; Lapeyre-Mestre M
Fundam Clin Pharmacol; 2004 Oct; 18(5):573-9. PubMed ID: 15482379
[TBL] [Abstract][Full Text] [Related]
57. What is the best approach to reducing birth defects associated with isotretinoin?
Abroms L; Maibach E; Lyon-Daniel K; Feldman SR
PLoS Med; 2006 Nov; 3(11):e483. PubMed ID: 17121451
[TBL] [Abstract][Full Text] [Related]
58. Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne.
DiGiovanna JJ; Langman CB; Tschen EH; Jones T; Menter A; Lowe NJ; Eichenfield L; Hebert AA; Pariser D; Savin RP; Smith SR; Jarratt M; Rodriguez D; Chalker DK; Kempers S; Ling M; Rafal ES; Sullivan S; Kang S; Shah LP; Wu E; Newhouse J; Pak J; Eberhardt DR; Bryce GF; McLane JA; Ondovik M; Chin C; Khoo KC; Rich P
J Am Acad Dermatol; 2004 Nov; 51(5):709-17. PubMed ID: 15523348
[TBL] [Abstract][Full Text] [Related]
59. Old and new anti-epileptic drugs in pregnancy.
Regesta G; Tanganelli P
Saudi Med J; 2000 Jan; 21(1):18-23. PubMed ID: 11533745
[TBL] [Abstract][Full Text] [Related]
60. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.
Schaefer C
Birth Defects Res A Clin Mol Teratol; 2003 Aug; 67(8):591-4. PubMed ID: 14632309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
